Estrella Immunopharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ESLA | APLM | IMMP | HURA | 6OP.F | CVM | |
|---|---|---|---|---|---|---|
| Market cap | 19.29M | 55.38M | 21.74M | 109.61M | 42.99M | 24.27M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.4 | -29.2 | -0.9 | -2.8 | — | -0.2 |
| Price/book | -2.6 | -12.8 | 0.5 | 6.0 | 1.4 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −83.67% | +71.38% | −91.38% | −33.80% | −67.91% | −80.79% |
| Today | +6.10% | −8.83% | −1.50% | +3.93% | −2.85% | −2.13% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ESLA news ›Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024.
From January 1, 2026 to March 31, 2026, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 515,281 shares, representing 1.44%... Published on 05/18/2026 at 06:05 am…
Estrella Immunopharma Announces CEO Changes
Estrella Immunopharma appointed Cynthia Pussinen as the Chief Executive Officer, effective October 25, 2026. She succeeds Cheng Liu, who will become Chief Scientific Officer while continuing as... Estrella Immunopharma appointed Cynthia…
Estrella Immunopharma, Inc.(NasdaqCM: ESLA) added to Russell 3000E Value Benchmark
Estrella Immunopharma, Inc. added to Russell 3000E Value Benchmark... Biotechnology & Medical Research Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell 3000E Value Benchmark Latest news about Estrella Immunopharma, Inc. Chart…
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Appointment comes at a pivotal stage as Estrella advances its differentiated ARTEMIS® T-cell therapy platform for cancer and autoimmune diseases Cheng Liu, Ph.D., appointed Chief Scientific Officer; continues as President and as a member…
Estrella Immunopharma, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Estrella Immunopharma, Inc. with the company of your choice via a Relative Strength chart. Real-time ESLA price, Nasdaq stock exchange Relative Strength Chart Estrella Immunopharma, Inc. Biotechnology & Medical Research All…
Estrella Immunopharma, Inc. Doses First Patient in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin?s Lymphoma
Estrella Immunopharma, Inc. announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a... announced that the first patient has been…
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center As Fourth Clinical Site For Phase I/II STARLIGHT-1 Trial In B-Cell Non-Hodgkin?s Lymphoma
Estrella Immunopharma activated a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or... Estrella Immunopharma activated a…
Estrella Immunopharma Treats First Patient with Two Eb103 Infusions in Starlight-1 Dose-Expansion Phase
Estrella Immunopharma, Inc. announced that the first patient who received two infusions, each at 5 × 106 EB103 T cells/kg, three weeks apart, in the dose-expansion phase has tolerated the study drug ... announced that the first patient who…
Estrella Immunopharma's Trial of EB103 to Treat Lymphoma Doses First Patient
Estrella Immunopharma said Friday that the first patient has been dosed in the dose-expansion phase of its STARLIGHT-1 phase 1/2 clinical trial of EB103 to treat patients with relapsed/refractory... Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- biospace.com1
- financialcontent.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.